Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Recombinant Zoster Vaccine Reduces the Incidence of Herpes Zoster After Autologous HSCT

Results from a randomised trial in preventing herpes zoster in immunocompromised patients after autologous haematopoietic stem cell transplantation
15 Jul 2019
Haematologic malignancies

Herpes zoster is a frequent complication following autologous haematopoietic stem cell transplantation (HSCT) and associated with significant morbidity. A non-live adjuvanted recombinant zoster vaccine has been developed to prevent post-transplantation zoster. In a randomised clinical trial of 1846 patients, the incidence of herpes zoster over a median follow-up of 21 months was 30 per 1000 person-years after 2 recombinant zoster vaccine doses vs 94 per 1000 person-years after placebo. This difference was statistically significant. The results are published on 9 July 2019 in JAMA.

To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients, the ZOE-HSCT Study Group Collaborators performed a phase III, randomised, observer-blinded study (NCT01610414) in 167 centres in 28 countries among patients aged 18 years or older who had undergone recent autologous HSCT.

Participants were randomised to receive 2 doses of either recombinant zoster vaccine or placebo administered into the deltoid muscle. The first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter. The study primary endpoint was occurrence of confirmed herpes zoster cases.

Among 1846 autologous HSCT recipients (mean age, 55 years; 37% women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study.

During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (p < 0.001), equivalent to 68.2% vaccine efficacy.

Of 8 secondary endpoints, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; p = 0.02) and of other prespecified herpes zoster–related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; p = 0.02) and in duration of severe worst herpes zoster–associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; p = 0.01). Five secondary objectives were descriptive.

Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3 in 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points.

The study team concluded that among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine significantly reduced the incidence of herpes zoster over a median follow-up of 21 months.


Bastidas A, de la Serna J, El Idrissi M, et al. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 2019;322(2):123-133. doi:10.1001/jama.2019.9053.

Last update: 15 Jul 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.